Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2020 (Event Date)
Signature Date: January 19, 2021
Context: The filing reports on the completion of share sales under an At-The-Market (ATM) offering program.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, cash flow, or margins. It specifically details capital raising activity:
- Shares Sold: 3,109,890 shares of common stock.
- Aggregate Gross Proceeds: $49,999,986.
- Weighted Average Sales Price: Approximately $16.08 per share.
- Sales Agent Commission: 3.0% of aggregate gross proceeds paid to Jefferies LLC.
Material Changes
The filing discloses a material change in the company's capital structure resulting from the ATM offering. As of January 15, 2021, the company had successfully raised approximately $50 million in gross proceeds through the sale of over 3.1 million shares. The filing text does not provide comparative data to a prior period for this specific transaction type.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the Open Market Sale Agreement with Jefferies LLC. No forward-looking guidance, outlook, or specific risk factors are detailed in this specific 8-K excerpt beyond the standard disclosure of the offering terms.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the net proceeds after deducting the 3.0% commission paid to Jefferies LLC.
- Confirm the total number of authorized shares remaining under the ATM Sales Agreement.
- Review the company's most recent 10-K or 10-Q to understand how these proceeds impact overall liquidity and cash position.
- Check for any subsequent filings regarding the continuation or termination of the ATM program.